Seproxetine

DB06731

small molecule investigational

Deskripsi

Seproxetine is also known as (S)-norfluoxetine. It is a selective serotonin reuptake inhibitor (SSRI). It is an active metabolite of fluoxetine. Seproxetine was being investigated by Eli Lilly as an antidepressant but development was never completed and the drug was never marketed.

Struktur Molekul 2D

Berat 295.305
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 4-16 days
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

1560 Data
Cilostazol The serum concentration of Cilostazol can be increased when it is combined with Seproxetine.
Cyproheptadine The therapeutic efficacy of Seproxetine can be decreased when used in combination with Cyproheptadine.
Desmopressin The risk or severity of hyponatremia can be increased when Seproxetine is combined with Desmopressin.
Ioflupane I-123 Seproxetine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.
Linezolid The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Seproxetine.
Metyrosine The risk or severity of extrapyramidal symptoms can be increased when Metyrosine is combined with Seproxetine.
Pimozide The risk or severity of QTc prolongation can be increased when Seproxetine is combined with Pimozide.
Buprenorphine Seproxetine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Seproxetine.
Dronabinol The serum concentration of Dronabinol can be increased when it is combined with Seproxetine.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Seproxetine.
Hydrocodone Seproxetine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Seproxetine.
Magnesium sulfate The therapeutic efficacy of Seproxetine can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Seproxetine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Seproxetine.
Mirtazapine Seproxetine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Seproxetine.
Orphenadrine Seproxetine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Seproxetine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Seproxetine.
Pramipexole Seproxetine may increase the sedative activities of Pramipexole.
Ropinirole Seproxetine may increase the sedative activities of Ropinirole.
Rotigotine Seproxetine may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Seproxetine.
Sodium oxybate Seproxetine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Seproxetine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Seproxetine.
Thalidomide Seproxetine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Seproxetine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Brexpiprazole The metabolism of Brexpiprazole can be decreased when combined with Seproxetine.
Eliglustat The metabolism of Eliglustat can be decreased when combined with Seproxetine.
Everolimus The metabolism of Everolimus can be decreased when combined with Seproxetine.
Flibanserin The metabolism of Flibanserin can be decreased when combined with Seproxetine.
Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Seproxetine.
Ivabradine The metabolism of Ivabradine can be decreased when combined with Seproxetine.
Ivacaftor The metabolism of Ivacaftor can be decreased when combined with Seproxetine.
Lurasidone The metabolism of Lurasidone can be decreased when combined with Seproxetine.
Naloxegol The metabolism of Naloxegol can be decreased when combined with Seproxetine.
Olaparib The metabolism of Olaparib can be decreased when combined with Seproxetine.
Ranolazine The metabolism of Ranolazine can be decreased when combined with Seproxetine.
Sonidegib The metabolism of Sonidegib can be decreased when combined with Seproxetine.
Avanafil The metabolism of Avanafil can be decreased when combined with Seproxetine.
Eplerenone The metabolism of Eplerenone can be decreased when combined with Seproxetine.
Colchicine The metabolism of Colchicine can be decreased when combined with Seproxetine.
Fentanyl The risk or severity of serotonin syndrome can be increased when Fentanyl is combined with Seproxetine.
Iloperidone The metabolism of Iloperidone can be decreased when combined with Seproxetine.
Retapamulin The metabolism of Retapamulin can be decreased when combined with Seproxetine.
Tofacitinib The metabolism of Tofacitinib can be decreased when combined with Seproxetine.
Vardenafil The metabolism of Vardenafil can be decreased when combined with Seproxetine.
Zopiclone The metabolism of Zopiclone can be decreased when combined with Seproxetine.
Lovastatin The metabolism of Lovastatin can be decreased when combined with Seproxetine.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Seproxetine.
Alfuzosin The metabolism of Alfuzosin can be decreased when combined with Seproxetine.
Alprazolam The metabolism of Alprazolam can be decreased when combined with Seproxetine.
Warfarin The serum concentration of Warfarin can be increased when it is combined with Seproxetine.
Acenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with Seproxetine.
(R)-warfarin The serum concentration of (R)-warfarin can be increased when it is combined with Seproxetine.
R,S-Warfarin alcohol The serum concentration of R,S-Warfarin alcohol can be increased when it is combined with Seproxetine.
S,R-Warfarin alcohol The serum concentration of S,R-Warfarin alcohol can be increased when it is combined with Seproxetine.
(S)-Warfarin The serum concentration of (S)-Warfarin can be increased when it is combined with Seproxetine.
Midazolam The serum concentration of Midazolam can be increased when it is combined with Seproxetine.
Tacrolimus The serum concentration of Tacrolimus can be increased when it is combined with Seproxetine.
Atorvastatin The metabolism of Atorvastatin can be decreased when combined with Seproxetine.
Tedizolid phosphate The risk or severity of serotonin syndrome can be increased when Tedizolid phosphate is combined with Seproxetine.
Naltrexone The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Seproxetine.
Bezitramide The risk or severity of serotonin syndrome can be increased when Bezitramide is combined with Seproxetine.
Eluxadoline The risk or severity of serotonin syndrome can be increased when Eluxadoline is combined with Seproxetine.
Morphine The risk or severity of serotonin syndrome can be increased when Morphine is combined with Seproxetine.
Codeine The risk or severity of serotonin syndrome can be increased when Codeine is combined with Seproxetine.
Hydromorphone The risk or severity of serotonin syndrome can be increased when Hydromorphone is combined with Seproxetine.
Meperidine The risk or severity of serotonin syndrome can be increased when Meperidine is combined with Seproxetine.
Oxycodone The risk or severity of serotonin syndrome can be increased when Oxycodone is combined with Seproxetine.
Butorphanol The risk or severity of serotonin syndrome can be increased when Butorphanol is combined with Seproxetine.
Dextropropoxyphene The risk or severity of serotonin syndrome can be increased when Dextropropoxyphene is combined with Seproxetine.
Pentazocine The risk or severity of serotonin syndrome can be increased when Pentazocine is combined with Seproxetine.
Sufentanil The risk or severity of serotonin syndrome can be increased when Sufentanil is combined with Seproxetine.
Nalbuphine The risk or severity of serotonin syndrome can be increased when Nalbuphine is combined with Seproxetine.
Levorphanol The risk or severity of serotonin syndrome can be increased when Levorphanol is combined with Seproxetine.
Remifentanil The risk or severity of serotonin syndrome can be increased when Remifentanil is combined with Seproxetine.
Diphenoxylate The risk or severity of serotonin syndrome can be increased when Diphenoxylate is combined with Seproxetine.
Oxymorphone The risk or severity of serotonin syndrome can be increased when Oxymorphone is combined with Seproxetine.
Dezocine The risk or severity of serotonin syndrome can be increased when Dezocine is combined with Seproxetine.
Levacetylmethadol The risk or severity of serotonin syndrome can be increased when Levacetylmethadol is combined with Seproxetine.
Methadyl acetate The risk or severity of serotonin syndrome can be increased when Methadyl acetate is combined with Seproxetine.
Dihydroetorphine The risk or severity of serotonin syndrome can be increased when Dihydroetorphine is combined with Seproxetine.
Diamorphine The risk or severity of serotonin syndrome can be increased when Diamorphine is combined with Seproxetine.
Ethylmorphine The risk or severity of serotonin syndrome can be increased when Ethylmorphine is combined with Seproxetine.
Etorphine The risk or severity of serotonin syndrome can be increased when Etorphine is combined with Seproxetine.
Dextromoramide The risk or severity of serotonin syndrome can be increased when Dextromoramide is combined with Seproxetine.
Desomorphine The risk or severity of serotonin syndrome can be increased when Desomorphine is combined with Seproxetine.
Carfentanil The risk or severity of serotonin syndrome can be increased when Carfentanil is combined with Seproxetine.
Dihydrocodeine The risk or severity of serotonin syndrome can be increased when Dihydrocodeine is combined with Seproxetine.
Alphacetylmethadol The risk or severity of serotonin syndrome can be increased when Alphacetylmethadol is combined with Seproxetine.
Dihydromorphine The risk or severity of serotonin syndrome can be increased when Dihydromorphine is combined with Seproxetine.
Ketobemidone The risk or severity of serotonin syndrome can be increased when Ketobemidone is combined with Seproxetine.
DPDPE The risk or severity of serotonin syndrome can be increased when DPDPE is combined with Seproxetine.
Lofentanil The risk or severity of serotonin syndrome can be increased when Lofentanil is combined with Seproxetine.
Opium The risk or severity of serotonin syndrome can be increased when Opium is combined with Seproxetine.
Normethadone The risk or severity of serotonin syndrome can be increased when Normethadone is combined with Seproxetine.

Target Protein

Sodium-dependent noradrenaline transporter SLC6A2
Sodium-dependent serotonin transporter SLC6A4
Sodium-dependent dopamine transporter SLC6A3

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul